Jose Acostamadiedo is an Oncology physician. OpenAlex indexes 5 publications with 597 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
212 Cornelia St
Plattsburgh, NY 129012306
Telephone
518-562-7100Registry record last updated 11 Oct 2017.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20241 payment
- Daiichi Sankyo Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.2%Aromatase Inhibitor12.6%Anastrozole83%Letrozole17%Part D<11 patientsKinase inhibitor11.2%Imatinib Mesylate54%Brukinsa30%Imbruvica15%Part D<11 patients+ 5 more classes in this area
Nervous system
18%Phenothiazine10.1%Prochlorperazine Maleate100%Part D≥38 patientsOpioid Agonist7.9%Oxycodone Hcl50%Tramadol Hcl25%Fentanyl25%Part D<11 patientsMetabolism & gastrointestinal
17.8%Serotonin-3 Receptor Antagonist12.5%Ondansetron Odt100%Part D≥50 patientsPotassium supplement3.3%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Skin cancer is among the most costly of all cancers to treat for the Medicare population
Journal of the American Academy of Dermatology
2003 - Phase II Study of Pyrazine Diazohydroxide (NSC 361456) for Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer
2000
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”